Quick Answer
International Stem Cell CORP reported Total Revenue of $9.10 million for fiscal year 2025.
International Stem Cell CORP — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $9.10M +0.2% |
$9.09M +16.6% |
$7.79M -4.8% |
$8.18M +14.0% |
$7.18M +0.7% |
$7.13M -24.7% |
| Revenue (ASC 606) | $9.10M +0.2% |
$9.09M +16.6% |
$7.79M -4.8% |
$8.18M +14.0% |
$7.18M +0.7% |
$7.13M -24.7% |
| Net Income | -$418.0K -100.0% |
-$209.0K -59.5% |
-$131.0K +60.4% |
-$331.0K +63.2% |
-$899.0K +67.0% |
-$2.72M +36.1% |
| Diluted EPS | -$0.05 -66.7% |
-$0.03 -50.0% |
-$0.02 +50.0% |
-$0.04 +63.6% |
-$0.11 | — |
| Total Assets | $4.82M -6.8% |
$5.17M -4.0% |
$5.39M +5.0% |
$5.13M +3.8% |
$4.95M -6.4% |
$5.29M -20.1% |
| Cash and Equivalents | — | — | — | — | — | — |
| Stockholders Equity | -$4.06M -3.3% |
-$3.93M +6.1% |
-$4.19M +7.4% |
-$4.52M +1.5% |
-$4.59M -5.9% |
-$4.33M -50.0% |
| R&D Expense | $684.0K +4.1% |
$657.0K +28.6% |
$511.0K +3.9% |
$492.0K -29.2% |
$695.0K -29.7% |
$988.0K -28.7% |
| Operating Income | -$267.0K -292.6% |
-$68.0K +89.7% |
-$663.0K -262.3% |
-$183.0K +90.5% |
-$1.92M +31.8% |
-$2.82M +50.8% |
| Shares Outstanding | 8.00M +0.0% |
8.00M +0.0% |
8.00M +0.0% |
8.00M +0.0% |
8.00M +6.2% |
7.54M +0.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $2.37M | +8.7% | -3.2% |
| Revenue (ASC 606) | September 30, 2025 | $2.37M | +8.7% | -3.2% |
| Net Income | September 30, 2025 | $57.0K | +145.6% | -55.8% |
| Diluted EPS | September 30, 2025 | $0.00 | +100.0% | -100.0% |
| Total Assets | September 30, 2025 | $5.28M | +2.0% | -4.8% |
| Cash and Equivalents | September 30, 2017 | $510.0K | -30.4% | +0.0% |
| Stockholders Equity | September 30, 2025 | -$3.78M | +6.6% | +3.1% |
| R&D Expense | September 30, 2025 | $158.0K | -15.5% | -2.5% |
| Operating Income | September 30, 2025 | $94.0K | +204.4% | -43.7% |
| Shares Outstanding | September 30, 2025 | 8.00M | +0.0% | +0.0% |
- International Stem Cell CORP reported Total Revenue of $9.10 million for fiscal year 2025.
- International Stem Cell CORP showed an increase of +0.2% in Total Revenue compared to the prior fiscal year.
- International Stem Cell CORP reported Revenue (ASC 606) of $9.10 million for fiscal year 2025.
- International Stem Cell CORP showed an increase of +0.2% in Revenue (ASC 606) compared to the prior fiscal year.
- International Stem Cell CORP reported Net Income of -$418.0 thousand for fiscal year 2025.
- International Stem Cell CORP showed a decrease of -100.0% in Net Income compared to the prior fiscal year.
- International Stem Cell CORP reported Diluted EPS of $0.05 per share (loss) for fiscal year 2025.
- International Stem Cell CORP showed a decrease of -66.7% in Diluted EPS compared to the prior fiscal year.
- International Stem Cell CORP reported Total Assets of $4.82 million for fiscal year 2025.
- International Stem Cell CORP showed a decrease of -6.8% in Total Assets compared to the prior fiscal year.
- International Stem Cell CORP reported Cash and Equivalents of $304.0 thousand for fiscal year 2017.
- International Stem Cell CORP showed an increase of +176.4% in Cash and Equivalents compared to the prior fiscal year.
- International Stem Cell CORP reported Stockholders Equity of -$4.06 million for fiscal year 2025.
- International Stem Cell CORP showed a decrease of -3.3% in Stockholders Equity compared to the prior fiscal year.
- International Stem Cell CORP reported R&D Expense of $684.0 thousand for fiscal year 2025.
- International Stem Cell CORP showed an increase of +4.1% in R&D Expense compared to the prior fiscal year.
- International Stem Cell CORP reported Operating Income of -$267.0 thousand for fiscal year 2025.
- International Stem Cell CORP showed a decrease of -292.6% in Operating Income compared to the prior fiscal year.
- International Stem Cell CORP reported Shares Outstanding of 8.00 million shares for fiscal year 2025.
- International Stem Cell CORP showed an increase of +0.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: